Canaccord Genuity Reiterates 10x Genomics Inc - (TXG) Buy Recommendation
Nasdaq Fintel reports that on September 19, 2023, Canaccord Genuity reiterated coverage of 10x Genomics Inc - (NASDAQ:TXG) with a Buy recommendation.
Analyst Price Forecast Suggests 38.57% Upside
As of August 31, 2023, the average one-year price target for 10x Genomics Inc - is 64.00. The forecasts range from a low of 30.30 to a high of $78.75. The average price target represents an increase of 38.57% from its latest reported closing price of 46.19.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for 10x Genomics Inc - is 623MM, an increase of 9.60%. The projected annual non-GAAP EPS is -1.20.
What is the Fund Sentiment?
There are 574 funds or institutions reporting positions in 10x Genomics Inc -. This is an increase of 16 owner(s) or 2.87% in the last quarter. Average portfolio weight of all funds dedicated to TXG is 0.26%, a decrease of 9.05%. Total shares owned by institutions decreased in the last three months by 1.29% to 104,286K shares. The put/call ratio of TXG is 0.13, indicating a bullish outlook.